Thus, the fact that only 5% of COVID-19 patients with aPL recognize B2GP1 domain I suggests that aPL could be different from those detected in APS patients in the context of COVID-19 [27]. This evidence concerns the gene FASLG and autoimmune polyendocrinopathy.